Pulse Biosciences reported a GAAP net loss of $10.6 million for the third quarter of 2023, compared to a $18.0 million loss in the same period of the previous year. The company's cash and cash equivalents totaled $50.4 million as of September 30, 2023. They are on track to file a 510(k) submission for clearance for their cardiac ablation clamp and initiate the cardiac ablation catheter first-in-human study between December 2023 and end of first quarter 2024.